


Abstract Submission, Rules & Regulations National Gynecologic Oncology Fellows Forum



The information below outlines the rules and regulations for abstract submission to the National Gynecologic Oncology Fellows Forum 2026 Annual Meeting.

Abstracts are selected on the basis of scientific merit and are allocated to Oral presentation in the General Session through a blinded peer-review process. The Fellows Forum Program Committee reserves the right to select the most appropriate forum for presentation.

Author Eligibility & Requirements

1. The presenting author is required to be a Fellow in Training in Gynecologic Oncology in a US Based institution or practice. All Fellows who are a part of the women's cancer gynecologic oncology care team are eligible and encouraged to submit an abstract.
2. Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter and are not reimbursed nor covered by Fellows Forum.
3. If abstract is selected for presentation, the Fellows Forum will pay for airfare (Coach Class Ticket up to \$650 for a round trip domestic flight), up to 4 nights hotel and ground transportation to/from originating city and destination city of meeting. Meals are provided at the meeting, additional expenses are the responsibility of the individual.

General Submission Requirements

1. All submissions must be assigned one of the following topic categories. These categories are only used to facilitate the peer-review process and are not intended to limit the type or topics of research submitted for consideration. No topic will be given priority over others for any reason other than potential impact on the field, quality of the content, and relevance to Fellows Forum's mission.
 - Cervical
 - Endometrial
 - Financial Toxicity and Disparities
 - Genetics
 - Other
 - Ovarian
 - Quality & Healthcare systems
 - Quality of Life/Palliative Care
 - Uterine
 - Vulvar
2. Submitted abstracts can represent new, unpublished scientific data at the time of presentation; however, submitted abstracts can be previously presented. Novel approaches do not need significant sample sizes resembling clinical trial design; rather, they should show innovative ways to advance science in gynecologic oncology to ultimately lead to the Fellows Forum Mission to help fellows with their presentation skills alongside the GOG's mission of transforming the standard of care in Gynecologic Cancers.
3. Author disclosure for the presenting author and all other authors must be declared at the time of abstract submission. An abstract that is missing any of the authors' disclosures will be considered

incomplete and will not be considered.

If any of the authors is employed by a company as defined by the [CMSS Code for Interactions with Companies](#) or according to Fellows Forum conflict of interest policy, which complies with ACCME/Joint Accreditation [regulations regarding the influence on CME content by persons with commercial interest](#), either s/he will be required to not make any recommendations relevant to the relationship or an alternate presenter who does not have a relevant financial relationship must be named if the abstract is accepted.

4. Write text in proper English (American or British usage is accepted, but not a mixture of these). Use decimal points (not commas). Please carefully check your spelling.
5. The abstract title must indicate the nature of the investigation but does not include author or affiliation identifying terms. Use sentence case and capitalize the first word in the title only. Example: The current clinical use of HPV genotyping.
6. Do not use abbreviations in the title of the abstract, with the exception of DNA, RNA, and HPV. Standard abbreviations may be used without definition in the text. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
7. Omit any reference to your institution within the title and text of the abstract to ensure proper, blinded review.
8. A maximum of twenty-four (24) co-authors, in addition to the primary author, are allowed per submission. All are responsible for completing their financial disclosure forms electronically and agree to all accreditation and presentation terms.
9. Author names should be written in full, indicating only the primary degree for each author (for example, MD, PhD). If an author's name appears on more than one abstract, it must be identical on each abstract.
10. Use generic drug names and International Systems Units. Trade names and logos should not be used. If this is unavoidable, it must be noted how and why.
11. Upon acceptance to present from both Fellows Forum and the presenting author, the author string and title of all accepted abstracts may be published online or in Fellows Forum marketing materials. Abstracts will not be made available until a maximum of two weeks prior to the Annual Meeting.
12. All PDF presentations from all sessions may be available to Annual Meeting attendees for up to one month following the conclusion of the meeting through the Fellows Forum website.

Abstract Submission Regulations

1. Each Abstract Submission must clearly identify the following:
 - Objectives: an introductory sentence indicating the purpose of the study
 - Methods: a brief description of pertinent experimental procedures, including statistical evaluation where appropriate
 - Results: a summary of the NEW, UNPUBLISHED DATA (Note previously published data will be considered)
 - Conclusions: a statement of the conclusions
2. Each submission is limited to one (1) table *or* graph.
3. There is a 2,000-character count limit for all submissions. This does not include your title, author string, spaces, nor single allotted table *or* graph.

For any questions regarding the above guidelines and regulations or any other matter pertaining to abstract submission for the Fellows Forum Annual, please email us at jcummins@gog.org.